Tamara L. Antonevskaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tamara L. Antonevskaya has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr Igorevich Khalimon
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
5 shared publications - Aleksey Victorovich Leontyev
Department of Nuclear Medicine, P. Hertsen Moscow Oncology Research Institute - The Branch of the FSBI “National Medical Research Radiological Centre” of the Ministry of Health of the Russian Federation, Moscow, Russia
5 shared publications - Gulnara Faridovna Khamadeeva
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
4 shared publications - Malika Maratovna Khodzhibekova
P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
4 shared publications - Tatiana Nikolaevna Lazutina
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
4 shared publications - Irina Valentinovna Pylova
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
3 shared publications
Latest Publications
- 26 May 2026
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 25 (2) , 78-87
Diagnosis of Infantile Hemispheric Glioma via Combined (Pre- and Intraoperative) Neuronavigation: Case Study
Background. Infantile hemispheric glioma (IHG) is a glial tumor (often large sized) that often develops in utero or during infancy. Timely diagnosis is challenging due to its rarity in young children and the variability of its molecular genetic characteristics. Implementation of preoperative and intraoperative neuroimaging allows to remove the most morphologically significant areas of tumor tissue when total resection is not possible, while cytogenetic analysis allows for a definitive diagnosis. Case description. The child with intrauterine growth retardation has grade 2 cerebral ischemia and movement disorders syndrome. Neurosonography at 13 days of age has revealed large cystic lesion that was not identified as a tumor. An increase in head circumference up to 7 cm was noted at the age of 2.5 months, while neurosonography has shown enlargement of the cystic cavity in the left hemisphere, thus ventriculoperitoneal shunting was performed. Magnetic resonance imaging of the brain has revealed a large cystic and solid lesion in the left hemisphere at the age of 8 months. We used combined neuronavigation to establish the diagnosis and determine treatment tactics: preoperative positron emission tomography with [ 18 F]fluoroethyl-l-tyrosine combined with computed tomography and ultrasound and fluorescence guidance during the surgery. Tumor cytogenetic analysis was performed and confirmed the glial nature of the neoplasm. Conclusion. This case shows the complexity of IHG diagnosis and the benefits of preoperative and intraoperative neuronavigation, as well as cytogenetic testing, to establish the final diagnosis.
- 26 May 2026
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 25 (2) , 78-87
Diagnosis of Infantile Hemispheric Glioma via Combined (Pre- and Intraoperative) Neuronavigation: Case Study
Background. Infantile hemispheric glioma (IHG) is a glial tumor (often large sized) that often develops in utero or during infancy. Timely diagnosis is challenging due to its rarity in young children and the variability of its molecular genetic characteristics. Implementation of preoperative and intraoperative neuroimaging allows to remove the most morphologically significant areas of tumor tissue when total resection is not possible, while cytogenetic analysis allows for a definitive diagnosis. Case description. The child with intrauterine growth retardation has grade 2 cerebral ischemia and movement disorders syndrome. Neurosonography at 13 days of age has revealed large cystic lesion that was not identified as a tumor. An increase in head circumference up to 7 cm was noted at the age of 2.5 months, while neurosonography has shown enlargement of the cystic cavity in the left hemisphere, thus ventriculoperitoneal shunting was performed. Magnetic resonance imaging of the brain has revealed a large cystic and solid lesion in the left hemisphere at the age of 8 months. We used combined neuronavigation to establish the diagnosis and determine treatment tactics: preoperative positron emission tomography with [ 18 F]fluoroethyl-l-tyrosine combined with computed tomography and ultrasound and fluorescence guidance during the surgery. Tumor cytogenetic analysis was performed and confirmed the glial nature of the neoplasm. Conclusion. This case shows the complexity of IHG diagnosis and the benefits of preoperative and intraoperative neuronavigation, as well as cytogenetic testing, to establish the final diagnosis.
- 2 May 2025
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 13 (3) , 283-301
Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent brain tumors: a systematic review and meta-analysis
- 2 May 2025
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 13 (3) , 283-301
Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent brain tumors: a systematic review and meta-analysis
- 16 December 2024
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent patients with brain tumors: a systematic review and meta-analysis
INPLASY2024120063 Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent patients with brain tumors: a systematic review and meta-analysis Keywords: [18F] FET PET; ped…
- 16 December 2024
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent patients with brain tumors: a systematic review and meta-analysis
INPLASY2024120063 Diagnostic and prognostic value of [18F] FET PET imaging in pediatric and adolescent patients with brain tumors: a systematic review and meta-analysis Keywords: [18F] FET PET; ped…
- Open Access
- 20 May 2024
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 11 (2) , 8-21
The impact of preliminary patient hydration on physiological [18F]PSMA-1007 uptake in the urinary bladder on PET/CT
Оne of the most commonly used fluorine‑18 labeled prostate-specific membrane antigen (PSMA) ligands in positron emission tomography combined with computed tomography (PET/CT) is [18F]PSMA‑1007. In comparison to other clinically available PSMA radioligands characterized by renal clearance, [18F]PSMA‑1007 exhibits predominantly hepatobiliary excretion. It allows a better assessment of the pelvic area in patients with prostate cancer (PCa). Nevertheless, in our clinical practice, we routinely observed a notably high [ 18F]PSMA‑1007 uptake in the urinary bladder. The underlying reasons for this phenomenon remain inadequately explored.Purpose of the study. The purpose of this study was to assess the impact of preliminary hydration of patients on [18F]PSMA‑1007 uptake in the urinary bladder.Materials and methods. Prospective, multicenter, randomized controlled study included 180 patients with PCa who underwent [18F]PSMA‑1007 PET/CT. Scans were performed using three different PET/CT-systems: GE Discovery IQ Gen 2 (USA), Siemens Biograph 64 mCT and Biograph 64 TruePoint (Germany). All patients were divided into two groups: the group with hydration (n = 95, 53 %), which included the subgroups of patients with oral (n = 76, 80 %) and intravenous (n = 19, 20 %) routes of hydration, and the control group with no hydration (n = 85, 47 %). [18F]PSMA‑1007 uptake in the urinary bladder was quantified using SUVmean (Mean Standardized Uptake value), measured within a spherical VOI with a fixed volume of 2.5 cm3 delineating the bladder boundaries. Additionally, the TBRmean (Mean Target-to-Background Ratio), reflecting the ratio between urinary bladder and right gluteal muscles SUVmean.Results. SUVmean and TBRmean in urinary bladder were significantly lower (p < 0,001) in the group with hydration compared to the control group, with the following values: 1.3 [0.8; 2.0] versus 4.5 [2.7; 8.5] for SUVmean and 4.0 [2.3; 6.3] versus 13.0 [7.7; 24.0] for TBRmean. There was no significant differences in SUVmean and TBRmean between the subgroups with oral and intravenous routes of hydration (p = 0.95 for SUVmean, p = 0.49 for TBRmean). Additionally, comparatively lower interquartile range (IQR) values for both SUVmean and TBRmean in the group with hydration were noted: 1.2 versus 5.8 for SUVmean, 4.0 versus 16.3 for TBRmean.Conclusion. Preliminary hydration of patients in uptake period significantly reduces both the level and variability of [18F]PSMA‑1007 uptake in the urinary bladder.
- 20 May 2024
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 11 (2) , 8-21
Open AccessThe impact of preliminary patient hydration on physiological [18F]PSMA-1007 uptake in the urinary bladder on PET/CT
Оne of the most commonly used fluorine‑18 labeled prostate-specific membrane antigen (PSMA) ligands in positron emission tomography combined with computed tomography (PET/CT) is [18F]PSMA‑1007. In comparison to other clinically available PSMA radioligands characterized by renal clearance, [18F]PSMA‑1007 exhibits predominantly hepatobiliary excretion. It allows a better assessment of the pelvic area in patients with prostate cancer (PCa). Nevertheless, in our clinical practice, we routinely observed a notably high [ 18F]PSMA‑1007 uptake in the urinary bladder. The underlying reasons for this phenomenon remain inadequately explored.Purpose of the study. The purpose of this study was to assess the impact of preliminary hydration of patients on [18F]PSMA‑1007 uptake in the urinary bladder.Materials and methods. Prospective, multicenter, randomized controlled study included 180 patients with PCa who underwent [18F]PSMA‑1007 PET/CT. Scans were performed using three different PET/CT-systems: GE Discovery IQ Gen 2 (USA), Siemens Biograph 64 mCT and Biograph 64 TruePoint (Germany). All patients were divided into two groups: the group with hydration (n = 95, 53 %), which included the subgroups of patients with oral (n = 76, 80 %) and intravenous (n = 19, 20 %) routes of hydration, and the control group with no hydration (n = 85, 47 %). [18F]PSMA‑1007 uptake in the urinary bladder was quantified using SUVmean (Mean Standardized Uptake value), measured within a spherical VOI with a fixed volume of 2.5 cm3 delineating the bladder boundaries. Additionally, the TBRmean (Mean Target-to-Background Ratio), reflecting the ratio between urinary bladder and right gluteal muscles SUVmean.Results. SUVmean and TBRmean in urinary bladder were significantly lower (p < 0,001) in the group with hydration compared to the control group, with the following values: 1.3 [0.8; 2.0] versus 4.5 [2.7; 8.5] for SUVmean and 4.0 [2.3; 6.3] versus 13.0 [7.7; 24.0] for TBRmean. There was no significant differences in SUVmean and TBRmean between the subgroups with oral and intravenous routes of hydration (p = 0.95 for SUVmean, p = 0.49 for TBRmean). Additionally, comparatively lower interquartile range (IQR) values for both SUVmean and TBRmean in the group with hydration were noted: 1.2 versus 5.8 for SUVmean, 4.0 versus 16.3 for TBRmean.Conclusion. Preliminary hydration of patients in uptake period significantly reduces both the level and variability of [18F]PSMA‑1007 uptake in the urinary bladder.
- Open Access
- 29 December 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (4) , 131-138-138
Atypical neoplastic solitary focal uptake of 18F-PSMA-1007 in PET/CT in patients with biochemically recurrent prostate cancer
It is established that prostate-specific membrane antigen (PSMA), despite its name, is expressed in many tissues other than the prostate gland, both within physiological conditions and in various pathological processes. Additionally, apart from prostate cancer, other malignant tumors are characterized by increased PSMA expression which, according to many authors, is associated with neoangiogenesis. These factors are reflected in the results of PSMA-radioligand imaging and require comprehensive approach to image interpretation including evaluation of computed tomography and magnetic resonance semiotics. In addition, rare cases of distant visceral prostate cancer metastasis in the form of solitary lesions also should be considered during interpretation of the results of radiologic imaging including positron emission tomography/computed tomography.We present two clinical cases in which positron emission tomography/computed tomography revealed solitary foci of pathological [18F]PSMA-1007 uptake outside the areas of typical metastatic spread (with exception of advanced disease)of prostate cancer, specifically in the stomach wall and the left cerebellar hemisphere. In the first case histologicalexamination results revealed a metachronous low grade neuroendocrine tumor of the stomach, in the second case a metastatic lesion of the cerebellum was diagnosed as part of the underlying disease.
- 29 December 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (4) , 131-138-138
Open AccessAtypical neoplastic solitary focal uptake of 18F-PSMA-1007 in PET/CT in patients with biochemically recurrent prostate cancer
It is established that prostate-specific membrane antigen (PSMA), despite its name, is expressed in many tissues other than the prostate gland, both within physiological conditions and in various pathological processes. Additionally, apart from prostate cancer, other malignant tumors are characterized by increased PSMA expression which, according to many authors, is associated with neoangiogenesis. These factors are reflected in the results of PSMA-radioligand imaging and require comprehensive approach to image interpretation including evaluation of computed tomography and magnetic resonance semiotics. In addition, rare cases of distant visceral prostate cancer metastasis in the form of solitary lesions also should be considered during interpretation of the results of radiologic imaging including positron emission tomography/computed tomography.We present two clinical cases in which positron emission tomography/computed tomography revealed solitary foci of pathological [18F]PSMA-1007 uptake outside the areas of typical metastatic spread (with exception of advanced disease)of prostate cancer, specifically in the stomach wall and the left cerebellar hemisphere. In the first case histologicalexamination results revealed a metachronous low grade neuroendocrine tumor of the stomach, in the second case a metastatic lesion of the cerebellum was diagnosed as part of the underlying disease.
- Open Access
- 14 April 2023
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 14 (1) , 63-72
Comparative assessment of 18F-PSMA-1007 biodistribution at 60 and 120 minutes after administration by PET/CT in prostate cancer patients
Сравнительная оценка биораспределения 18F-ПСМА-1007 через 60 и 120 минут после внутривенного введения при ПЭТ/КТ у пациентов, обследованных по поводу рака предстательной железы
- 14 April 2023
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 14 (1) , 63-72
Open AccessComparative assessment of 18F-PSMA-1007 biodistribution at 60 and 120 minutes after administration by PET/CT in prostate cancer patients
Сравнительная оценка биораспределения 18F-ПСМА-1007 через 60 и 120 минут после внутривенного введения при ПЭТ/КТ у пациентов, обследованных по поводу рака предстательной железы
- Open Access
- 3 November 2022
- Published by SCEEMP in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
- Vol. 12 (4) , 444-454
18F-FDG PET/CT in the Diagnosis of Cervical Cancer
Роль ПЭТ/КТ с 18 F-ФДГ в диагностике рака шейки матки
- 3 November 2022
- Published by SCEEMP in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
- Vol. 12 (4) , 444-454
Open Access18F-FDG PET/CT in the Diagnosis of Cervical Cancer
Роль ПЭТ/КТ с 18 F-ФДГ в диагностике рака шейки матки
- 18 May 2021
- Published by Vidar, Ltd. in Medical Visualization
- Vol. 25 (2) , 90-97
Dual tracer hybrid radionuclide imaging of a metastatic gastrointestinal neuroendocrine tumor with unknown primary site using 18F-FDG PET/CT and 99mTc-HYNIC-TOC SPECT/CT (case report and literature review)
Neuroendocrine tumors (NEТ) are a heterogeneous group of neoplasms of various locations originating from the APUD system cells with biologically active properties. Although immunohistochemical assay for Ki-67 has been proved to have prognostic significance in GEP-NENs, pitfalls may lead to misjudgment of the tumor grades, prognosis and during treatment planning due to the presence of cells with varying degrees of differentiation and proliferative activity within a single lesion, as well as the entire neoplastic process. These features can affect the results of imaging and therapy planning. An increase in the number of somatostatin receptors on the surface of membrane cells, as well as an increase in glycolysis may occur in NETs. These phenomena play role when choosing imaging methods, as well as in treatment planning. Combined dual-tracer imaging, specifically PET/CT or SPECT/CT using labeled somatostatin analogues can be used in intermediate assessment of cellular heterogeneity in the entire neoplastic process in NENs and help to minimize diagnostic pitfalls listed above. We present an observation of a patient with metastatic GEP-NEN of unknown primary in which 18 F-FDG PET/CT and 99m Tc-HYNIC-TOC SPECT/CT were performed for initial staging. In the framework of this, aspects of use of dual-tracer radionuclide imaging in patients with NENs are widely discussed.
- 18 May 2021
- Published by Vidar, Ltd. in Medical Visualization
- Vol. 25 (2) , 90-97
Dual tracer hybrid radionuclide imaging of a metastatic gastrointestinal neuroendocrine tumor with unknown primary site using 18F-FDG PET/CT and 99mTc-HYNIC-TOC SPECT/CT (case report and literature review)
Neuroendocrine tumors (NEТ) are a heterogeneous group of neoplasms of various locations originating from the APUD system cells with biologically active properties. Although immunohistochemical assay for Ki-67 has been proved to have prognostic significance in GEP-NENs, pitfalls may lead to misjudgment of the tumor grades, prognosis and during treatment planning due to the presence of cells with varying degrees of differentiation and proliferative activity within a single lesion, as well as the entire neoplastic process. These features can affect the results of imaging and therapy planning. An increase in the number of somatostatin receptors on the surface of membrane cells, as well as an increase in glycolysis may occur in NETs. These phenomena play role when choosing imaging methods, as well as in treatment planning. Combined dual-tracer imaging, specifically PET/CT or SPECT/CT using labeled somatostatin analogues can be used in intermediate assessment of cellular heterogeneity in the entire neoplastic process in NENs and help to minimize diagnostic pitfalls listed above. We present an observation of a patient with metastatic GEP-NEN of unknown primary in which 18 F-FDG PET/CT and 99m Tc-HYNIC-TOC SPECT/CT were performed for initial staging. In the framework of this, aspects of use of dual-tracer radionuclide imaging in patients with NENs are widely discussed.